Wall Street Wobbles Amidst War Woes and Rate Hike Rumblings

• Rising geopolitical tensions in the Middle East are driving up oil prices, impacting market stability.
• Increased likelihood of interest rate hikes adds pressure on stock performance.
• Eli Lilly faces scrutiny over its obesity drug Foundayo, triggering market volatility.
• Despite initial concerns, Eli Lilly asserts the safety of Foundayo based on comprehensive clinical data.

Shagadelic Market Swings

Groovy, baby, yeah. Austin Powers here, reporting live from the front lines of finance. The stock market's doing the rumba, twisting and shouting as concerns about the war in Iran send shockwaves through Wall Street. Oil prices, those naughty little numbers, have jumped higher than my libido on a Saturday night, all thanks to missile and drone attacks reported by the United Arab Emirates. It's enough to make you lose your mojo.

Interest Rates Get Their Groove On

Oh, behave. The ten-year Treasury yield is jumping around like I'm at a disco, hitting nearly 4.45%, and the 30-year is partying above 5%. All this suggests that the odds of a rate hike this year are increasing faster than my ability to attract beautiful spies. Speaking of things going up, have you checked out Oil Prices Spiral Amidst Middle East Conflict? It's a wild ride, baby. The Fed may be forced to act sooner than we think with Kevin Warsh coming in as Chair – let's hope they don't spoil the party.

Eli Lilly's Liver Lurgy Scare

Not so fast! Eli Lilly had a bit of a boo-boo with their new oral obesity drug, Foundayo. One patient reported liver failure, and the market went bananas. It's like someone shouting 'fire' in a crowded discotheque. Shares dropped faster than my pants on honeymoon night. The FDA is watching like a hawk, which is good, because nobody wants dodgy livers.

Foundayo's Fightback

Alright! But don't count Lilly out just yet, baby. They've come out swinging, claiming that their patient safety division reviewed the case and determined the adverse event was "not reasonably related to Foundayo." They say they've studied over 11,000 people, and the liver safety profile is similar to a placebo. Sounds like damage control, but maybe they've got something there.

GLP-1s and New Beginnings

Yeah, baby, yeah! Foundayo may not be as popular as Novo Nordisk's Wegovy, but more than 20,000 people have started taking it. And get this – over 80% of those users are new to GLP-1s. That means Foundayo isn't stealing sales from Lilly's injectable drugs, Zepbound and Mounjaro. That's what I call groovy.

Earnings Extravaganza and Economic Insights

Shaguar time! Keep your eyes peeled for earnings reports from Palantir, Onsemi, BWX Technologies, and Pinterest. Plus, we've got DuPont, Eaton, Shopify, PayPal, Pfizer, KKR, Fiserv, American Electric Power, and GlobalFoundries all reporting before the bell tomorrow. And don't forget the S & P Global US Services PMI, the ISM services index, and March new home sales. It's all happening, baby. It's all happening.